Eledon Pharmaceuticals (ELDN) to Release Quarterly Earnings on Monday

Eledon Pharmaceuticals (NASDAQ:ELDNGet Rating) will issue its quarterly earnings data after the market closes on Monday, November 14th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Eledon Pharmaceuticals (NASDAQ:ELDNGet Rating) last released its earnings results on Thursday, August 11th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.07. On average, analysts expect Eledon Pharmaceuticals to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eledon Pharmaceuticals Stock Performance

ELDN opened at $2.53 on Friday. The company has a 50-day moving average of $2.81 and a 200-day moving average of $2.97. The company has a market capitalization of $34.81 million, a P/E ratio of -0.93 and a beta of 1.86. Eledon Pharmaceuticals has a 1-year low of $2.27 and a 1-year high of $6.04.

Institutional Investors Weigh In On Eledon Pharmaceuticals

A number of institutional investors have recently modified their holdings of ELDN. Dimensional Fund Advisors LP bought a new stake in shares of Eledon Pharmaceuticals during the 3rd quarter valued at about $50,000. Renaissance Technologies LLC grew its position in shares of Eledon Pharmaceuticals by 35.1% during the 1st quarter. Renaissance Technologies LLC now owns 18,473 shares of the company’s stock valued at $73,000 after buying an additional 4,800 shares during the last quarter. State Street Corp grew its position in shares of Eledon Pharmaceuticals by 10.5% during the 1st quarter. State Street Corp now owns 44,692 shares of the company’s stock valued at $176,000 after buying an additional 4,257 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Eledon Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 679,243 shares of the company’s stock valued at $2,676,000 after buying an additional 9,543 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Eledon Pharmaceuticals in a research report on Tuesday, August 2nd.

Eledon Pharmaceuticals Company Profile

(Get Rating)

Eledon Pharmaceuticals, Inc, clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes.

Read More

Earnings History for Eledon Pharmaceuticals (NASDAQ:ELDN)

Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.